Vidac is a clinical stage innovative biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. We at Vidac are passionate about translating breakthrough science into innovative therapies that address major unmet medical needs.
Our breakthrough technology targets the VDAC/HK2 system that is unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue. This technology holds a promise of delivering first-in-class drugs that are both efficacious and well tolerated.
Vidac was founded by Prof. Max Herzberg, one of the founding fathers of the Israel life sciences industry, and licensed part of its technology from two top Israeli universities, Tel Aviv University and Ben Gurion University.
Vidac's lead drug, VDA-1102 ointment, has completed with positive results a Phase 2a clinical study in subjects with actinic keratosis (AK), an early form of skin cancer. A confirmatory Phase 2b trials is scheduled for 2018. The study is under an IND from the FDA.Factsheet